223 related articles for article (PubMed ID: 18041568)
1. [Botulinum toxin efficacy in the treatment of patients with spasmodic dysphonia].
Svetel M; Vasić M; Tomić G; Stanković P; Stojanović M; Dragasević N; Dergenc R; Vukasinović M; Pekmezović T; Petrović I; Kostić V
Vojnosanit Pregl; 2007 Oct; 64(10):671-5. PubMed ID: 18041568
[TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.
Blitzer A; Brin MF; Stewart CF
Laryngoscope; 1998 Oct; 108(10):1435-41. PubMed ID: 9778279
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
5. Botox treatment in adductor spasmodic dysphonia: a meta-analysis.
Boutsen F; Cannito MP; Taylor M; Bender B
J Speech Lang Hear Res; 2002 Jun; 45(3):469-81. PubMed ID: 12069000
[TBL] [Abstract][Full Text] [Related]
6. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic and therapeutic difficulties in laryngeal dystonia].
Niebudek-Bogusz E; Modzelewska-Radwan B; Pietruszewska W; Zielińska M; Gryczyński M
Otolaryngol Pol; 2003; 57(5):739-45. PubMed ID: 14994622
[TBL] [Abstract][Full Text] [Related]
8. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
[TBL] [Abstract][Full Text] [Related]
9. Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection.
Cannito MP; Kahane JC; Chorna L
Clin Interv Aging; 2008; 3(1):131-51. PubMed ID: 18488884
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A for treating voice tremor.
Adler CH; Bansberg SF; Hentz JG; Ramig LO; Buder EH; Witt K; Edwards BW; Krein-Jones K; Caviness JN
Arch Neurol; 2004 Sep; 61(9):1416-20. PubMed ID: 15364688
[TBL] [Abstract][Full Text] [Related]
11. Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique.
Young N; Blitzer A
Laryngoscope; 2007 Nov; 117(11):2082-4. PubMed ID: 17828055
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
13. Neurectomy and Myomectomy for Treatment of Spasmodic Dysphonia.
Ryan W; Alnouri G; Sataloff RT
J Voice; 2024 Jan; 38(1):239-242. PubMed ID: 35738960
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing long-term treatment response to botulinum toxin injection for spasmodic dysphonia.
Kang MS; Lee SJ; Choi HS; Lim JY
Clin Otolaryngol; 2021 Mar; 46(2):436-444. PubMed ID: 33260261
[TBL] [Abstract][Full Text] [Related]
15. [Treatment efficacy of electronic endoscope-guided botulinum toxin injection in adductor spasmodic dysphonia patients].
Ren J; Yang H; Wang H; Zou J; Lv D; Yu L; Zheng Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Nov; 34(11):1019-1023. PubMed ID: 33254323
[No Abstract] [Full Text] [Related]
16. Laryngeal dystonia: case report and treatment with botulinum toxin.
Santos VJ; Mattioli FM; Mattioli WM; Daniel RJ; Cruz VP
Braz J Otorhinolaryngol; 2006; 72(3):425-7. PubMed ID: 17119783
[TBL] [Abstract][Full Text] [Related]
17. Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin.
Dejonckere PH; Neumann KJ; Moerman MB; Martens JP; Giordano A; Manfredi C
Eur Arch Otorhinolaryngol; 2012 Apr; 269(4):1195-203. PubMed ID: 22210475
[TBL] [Abstract][Full Text] [Related]
18. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
[TBL] [Abstract][Full Text] [Related]
19. Spasmodic dysphonia combined with insufficient glottic closure by phonation.
Kaszás Z; Lichtenberger G; Mészáros K; Falvai J
Eur Arch Otorhinolaryngol; 2003 Sep; 260(8):418-20. PubMed ID: 12709812
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
Tsuji DH; Takahashi MT; Imamura R; Hachiya A; Sennes LU
J Voice; 2012 Sep; 26(5):666.e7-12. PubMed ID: 21940146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]